FDA ap­proves As­traZeneca, Ion­is' AT­TR drug as show­down with Al­ny­lam heats up

The FDA on Thurs­day ap­proved Io­n­is and As­traZeneca’s treat­ment for a fa­tal neu­rode­gen­er­a­tive dis­ease as the pair joins a space long dom­i­nat­ed by Al­ny­lam’s siR­NA med­i­cines.

US reg­u­la­tors grant­ed ap­proval to eplon­ter­sen for hered­i­tary transthyretin-me­di­at­ed amy­loid polyneu­ropa­thy, or AT­TRv-PN. Al­ny­lam al­ready has two drugs ap­proved to treat the dis­ease.

Eplon­ter­sen, which will be brand­ed as Wain­ua (pro­nounced way-NOO-uh), will be priced “con­sis­tent” with what’s al­ready on the mar­ket, As­traZeneca se­nior VP Mi­na Makar told End­points News. He de­clined to spec­i­fy the ex­act price.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER